These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

127 related articles for article (PubMed ID: 29391065)

  • 41. Comparative long-term efficacy and tolerability of pitavastatin 4 mg and atorvastatin 20-40 mg in patients with type 2 diabetes mellitus and combined (mixed) dyslipidaemia.
    Gumprecht J; Gosho M; Budinski D; Hounslow N
    Diabetes Obes Metab; 2011 Nov; 13(11):1047-55. PubMed ID: 21812889
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Cardioprotective effect of atorvastatin alone or in combination with remote ischemic preconditioning on the biochemical changes induced by ischemic/reperfusion injury in a mutual prospective study with a clinical and experimental animal arm.
    El Desoky ES; Hassan AKM; Salem SY; Fadil SA; Taha AF
    Int J Cardiol; 2016 Nov; 222():866-873. PubMed ID: 27522390
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Combination treatment with atorvastatin plus niacin provides effective control of complex dyslipidemias: a literature review.
    McKenney JM
    Postgrad Med; 2012 Jan; 124(1):7-20. PubMed ID: 22314110
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Genetic determinants of lipid-lowering response to atorvastatin therapy in an Indian population.
    Kadam P; Ashavaid TF; Ponde CK; Rajani RM
    J Clin Pharm Ther; 2016 Jun; 41(3):329-33. PubMed ID: 26932749
    [TBL] [Abstract][Full Text] [Related]  

  • 45. High-dose atorvastatin after stroke or transient ischemic attack.
    Amarenco P; Bogousslavsky J; Callahan A; Goldstein LB; Hennerici M; Rudolph AE; Sillesen H; Simunovic L; Szarek M; Welch KM; Zivin JA;
    N Engl J Med; 2006 Aug; 355(6):549-59. PubMed ID: 16899775
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Efficacy and safety of a new HMG-CoA reductase inhibitor, atorvastatin, in patients with hypertriglyceridemia.
    Bakker-Arkema RG; Davidson MH; Goldstein RJ; Davignon J; Isaacsohn JL; Weiss SR; Keilson LM; Brown WV; Miller VT; Shurzinske LJ; Black DM
    JAMA; 1996 Jan; 275(2):128-33. PubMed ID: 8531308
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Efficacy and safety of ABT-335 (fenofibric acid) in combination with atorvastatin in patients with mixed dyslipidemia.
    Goldberg AC; Bays HE; Ballantyne CM; Kelly MT; Buttler SM; Setze CM; Sleep DJ; Stolzenbach JC
    Am J Cardiol; 2009 Feb; 103(4):515-22. PubMed ID: 19195513
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Achievement rates of Japan Atherosclerosis Society Guidelines 2007 LDL-cholesterol goals with rosuvastatin or atorvastatin in patients who had not achieved their goal with atorvastatin.
    Shioji K; Izuhara M; Mitsuoka H; Uegaito T; Matsuda M;
    Cardiovasc Ther; 2014 Jun; 32(3):97-104. PubMed ID: 24456217
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Efficacy, safety and tolerability of atorvastatin in dyslipidemic subjects with advanced (non-nephrotic) and endstage chronic renal failure.
    Saltissi D; Westhuyzen J; Morgan C; Healy H
    Clin Exp Nephrol; 2006 Sep; 10(3):201-9. PubMed ID: 17009078
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Are all statins the same? Focus on the efficacy and tolerability of pitavastatin.
    da Silva PM
    Am J Cardiovasc Drugs; 2011; 11(2):93-107. PubMed ID: 21446776
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Clinical equivalence of proprietary and generic atorvastatin in lipid clinic patients.
    Rahalkar AR; Ban MR; Hegele RA
    Can J Cardiol; 2013 Apr; 29(4):418-22. PubMed ID: 22840301
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Evaluation of erythrocyte deformability in pre-menopausal and post-menopausal women.
    Gelmini G; Delsignore R; Coiro V
    Maturitas; 1987 Nov; 9(3):275-81. PubMed ID: 3431478
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Dyslipidemia in midlife women: Approach and considerations during the menopausal transition.
    Torosyan N; Visrodia P; Torbati T; Minissian MB; Shufelt CL
    Maturitas; 2022 Dec; 166():14-20. PubMed ID: 36027726
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Sodium ozagrel and atorvastatin for type 2 diabetes patients with lacunar cerebral infarction.
    Yu Y; Wang L; Zhu X; Liu YF; Ma HY
    World J Diabetes; 2021 Dec; 12(12):2096-2106. PubMed ID: 35047123
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Atorvastatin May Correct Dyslipidemia in Adult Patients at Risk for Alzheimer's Disease Through an Anti-Inflammatory Pathway.
    Zhao L; Zhao Q; Zhou Y; Zhao Y; Wan Q
    CNS Neurol Disord Drug Targets; 2016; 15(1):80-5. PubMed ID: 26666876
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Effect of "Natural Polypill", Xuezhikang on Serum Cholesterol Metabolism Markers in Early Menopausal Women with Hypercholesterolemia.
    Feng Y; Lu SL; Jin XG; Gao J; Chen WP; Wang YX; Xu H; Wang LY
    Chin J Integr Med; 2022 Mar; 28(3):202-207. PubMed ID: 34432203
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Effects of an evidence-based nursing intervention on neurological function and serum inflammatory cytokines in patients with acute cerebral infarction: A randomized controlled trial.
    Liu Y; Qu M; Wang N; Wang L
    Restor Neurol Neurosci; 2021; 39(2):129-137. PubMed ID: 33935121
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Effects of Kudiezi Injection on Serum Inflammatory Biomarkers in Patients with Acute Cerebral Infarction.
    Liu X; Jin X; Chen B; Liu X; Liang X; Fang X; Wu H; Fu X; Zheng H; Ding X; Duan N; Zhang Y
    Dis Markers; 2018; 2018():7936736. PubMed ID: 30245755
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Comparison of efficacy and safety between loading-dose atorvastatin and rosuvastatin in cerebral infarction.
    Li Y; Zhang D; Liu S; Ni W; Wang C; Yu B; Guan J; Shao J; Zhang Q
    Am J Transl Res; 2024; 16(9):4633-4642. PubMed ID: 39398547
    [TBL] [Abstract][Full Text] [Related]  

  • 60. The relationship between the female menopause and serum sialic acid, a known cardiovascular risk factor.
    Crook M; Collins D; Lumb P; Fogelman I; Treloar A
    Eur J Obstet Gynecol Reprod Biol; 1998 Feb; 76(2):185-7. PubMed ID: 9481572
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.